Description:
ModelHuntington"sDiseaseinaDish
Wehaveappliedourinnovativetechnologytodevelophumanneuralstemcellsdirectlydifferentiatedfrom Huntington’sDiseaseiPScells. OurcellsallowHuntington"sDiseaseresearcherstobuildtheirownhumancellularmodelsinadisease-relevantgeneticandtissuecontext.
Ourready-to-usekitsallowyoutoconcentrateonyourexperimentsratherthanspendingvaluabletimeandresourcesgeneratingHuntington"sDiseaseneuralProgenitorsin-house. Aspartofthe HDNSCkit,youwillreceive Plating-XFMedium inadditiontoyourvialofhumanneuralstemcellstomaximizecellviABIlity.
HDNSCs arereadymadeandeasytodifferentiate. Theyarecapableofdifferentiatingintoaspectrumofcorticalexcitatoryandinhibitoryneuronsandremainviableincultureformonths,facilitatingreproducIBLeandlong-termstudies.
WhetheryouwanttostudyHuntington"sDiseasepathogenesisatthecellularlevel,performneurotoxicitytestingorpre-clinicaldrugscreening,webelievethat HDNSCs,alongsideouroptimized culturereagents,providetheperfectculturesystemforyourresearchsuccess.

PhaseContrastImageofHuntington"sDiseaseHumanNeuralStemCells.
TheimagewastakenatDay7invitro.InthecentreoftheimageyoucanseeHDNSCsinaneuralrosetteformation.Neuriteoutgrowthcanalsobeobserved.
Huntington"sDiseaseNeuralStemCellsExpressNeuralStem/ProgenitorCellMarkers.
HDNSCswerefixedafter7daysincultureandstainedusingourimmunocytochemistyprotocol.TheneuralstemcellswerecounterstainedwithDAPItovisualisethenuclei.Thecellscanbeseentoexpressneuralstem/progenitorcellmarkersKi67,NestinandPax6.
                       DAPI Pax6 Nestin
DAPINestinKi67
AdvantagesofAxolHDNSCs
HumancellsderivedfromdiagnosedHuntington"sDiseasepatients
Availableinindustrialquantity
Highpurityneuralstemcellpopulation
Ready-madeandeasytodifferentiate
Robustenoughtoundergogeneticmanipulation
Capableofdifferentiatingtoaspectrumofcorticalexcitatoryandinhibitoryneurons
Remainviableincultureformonthstofacilitatereproducibleandlongtermstudies
Applications
StudyingHuntington"sDiseasepathogenesisatthecellularlevel
StudyingneuralnetworkformationandsignaltransmissioninHuntington"sDiseaseneuralculture
Neurotoxicitytesting
Preclinicaldrugefficacytesting
Co-culturestudieswithastrocytes
ProductSpecification:
| Startingmaterial | Fibroblasts | 
| Donorgender | Female | 
| Donorageatsampling | 48yrs | 
| Donorageofonset | 42yrs | 
| Reprogrammingmethod | Retroviral | 
| Inductionmethod | Monolayer&chemicallydefinedmedium | 
| Size | ≥1.5millioncells | 
| Kitcomponents | 1vialofNeuralStemCells(≥1.5millioncells)and1bottleofNeuralPlating-XFMedium(30mL) | 
| Celltype | iPSC-derivedneuralstemcells | 
| Growthproperties | Adherent | 
| Shippingconditions | Dryice | 
| Storageconditions | Liquidnitrogen | 

		